DNA Methylation Makes Cancer Cells More Vulnerable to Immune Response, Fox Chase Cancer Center Study Shows

Alfonso Bellacosa, MD, PhD, had a paper published in Gastroenterology.
Alfonso Bellacosa, MD, PhD, the study’s lead author and a professor in the Nuclear Dynamics and Cancer research program, has a paper accepted in Gastroenterology.

PHILADELPHIA (February 23, 2023)—Immunotherapy—using the body’s immune system to attack cancer cells—has become a powerful cancer-fighting tool. But, for reasons that are unclear, tumors evade immune cells, making them resistant to these therapies.

Now a new study by Fox Chase Cancer Center scientists shows how a process called DNA methylation can regulate the immune response in colorectal cancer, laying the groundwork for potential new treatments. DNA methylation and demethylation is a balanced process that regulates gene expression. Methylation suppresses genes and essentially turns them off, while demethylation activates them again.

“By blocking this demethylation pathway, we can make these cancer cells very sensitive to killing by natural killer cells, which are immune cells,” said Alfonso Bellacosa, MD, PhD, the study’s lead author and a professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase. The study’s first author is Rossella Tricarico, PhD, a former research associate in Bellacosa’s lab, who is now an assistant professor in human and cancer genetics in the Department of Biology and Biotechnology at the University of Pavia in Italy.

Methylation was already known to play an important role in a wide variety of cancer types, including colon cancer. But exactly what role it played, and how it worked at the molecular level, was not understood. For the study, researchers wanted to understand the mechanism in detail and investigate how it could be exploited for better diagnosis and treatment.

First, they looked at colon tumors from mice that were missing enzymes that trigger demethylation. These tumors had higher levels of methylation throughout the genome, but especially in regions called CpG islands, clusters of genes that may regulate immune response.

When they analyzed these “CIMP” tumors (short for CpG island methylator phenotype), they found that they showed more signs of inflammation and interferon response. These processes play a key role in the immune system’s ability to identify and attack disease cells.

“When that happens, the tumors are more visible and better detected by the immune system,” Bellacosa said. “So the immune cells are able to come and infiltrate the tumors.”

Researchers then examined a human cancer database to look for colon tumors that were genetically similar to the CIMP mouse tumors. “We found again that these tumors were the ones with the highest methylation, and they also had the highest inflammation,” Bellacosa said.

Interestingly, the tumors not only had lower levels of an enzyme that demethylates DNA, they also had higher levels of an enzyme that promotes methylation, he added.

“The key finding, in both the mouse and human models, is that high levels of DNA methylation correlate with high levels of inflammatory and interferon response,” he said. “This is independent of the pathways we currently associate with inflammatory response in colon cancer and represents a completely new and unexpected finding.”

In the final phase of the experiments, researchers exposed colon cancer cells to “killer” immune cells. By blocking the genes that trigger demethylation, they made the cancer cells much more vulnerable to killing by the immune cells. “This provides a potential new way of rendering tumor cells more sensitive to immunotherapy,” he said.

While the study looked at colon cancer cells, Bellacosa noted that the findings could have implications for a wide variety of cancers, including melanoma and lung cancer. Next, the researchers will work to better understand the molecular mechanism through which methylation activates the inflammatory and interferon response, Bellacosa said.

“We are also actively looking for inhibitors,” he added, “drugs that could inhibit this pathway and will then be the first step toward creating new epigenetic therapies that will increase sensitization to immunotherapy.” The study, “TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype,” was published in Gastroenterology.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427